Eli Lilly Reports Stellar Q1 Performance

Eli Lilly announced a remarkable 45% increase in its first-quarter revenue for fiscal 2025, reaching $12.73 billion. This surge was primarily driven by the volume growth of its flagship products, Mounjaro and Zepbound.

Financial Highlights and Future Outlook

The company also revealed a net income of $2.76 billion for the quarter, marking a 23% year-over-year growth. Despite facing $1.57 billion in acquired in-process R&D charges, earnings per share stood strong at $3.06.

CEO David Ricks shared insights on the promising future, especially highlighting the success of the oral GLP-1 candidate, forgilzumab. Lilly has reaffirmed its revenue guidance for the year, projecting between $58 billion and $61 billion. Additionally, a massive $50 billion expansion in US manufacturing is planned to cater to the escalating demand.